Entries by admin

Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer

Dallas/Fort Worth, TX  (May  22, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today the appointment of Richard I. Eisenstadt to the role of Chief Financial […]

Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis   FREMONT, Calif., May 15, 2014 /PRNewswire/ — Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a […]

ARCADIA BIOSCIENCES RAISES $33 MILLION SERIES D INVESTMENT

DAVIS, Calif. (May 8, 2014) – CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company focused on developing technologies and products that benefit the environment and human health, announced today that it has closed on a $33 million round of Series D preferred share equity financing. The round was led with an investment […]

‘Adderall’ up: Neos gets $18M series C plus $20M loan deal for AD

Neos Therapeutics Inc.’s upsized series C financing – from $15.5 million to $18 million – along with a $20 million loan facility with Hercules Technology Growth Capital Inc. means the firm will “not only have enough money to hit the key regulatory milestones over the next 12-15 months, but to give us financial flexibility into […]

Baxano Surgical, Inc. Announces Closing of $10 Million Private Placement of Convertible Debentures

RALEIGH, N.C., April 23, 2014 (GLOBE NEWSWIRE) — Baxano Surgical, Inc. (NASDAQ:BAXS) (“Baxano Surgical” or the “Company”), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has entered into a definitive agreement with entities affiliated with […]

China Is Now World Leader in Graphene and Carbon Nanotube Research

BOSTON, MA – April 23, 2014 – Driven by favorable government policies, funding and world-leading academic research, China has become the global leader in graphene and carbon nanotube (CNT) publication and patenting activity. Commercially, it has attained parity with international counterparts in CNT production, though its graphene suppliers lag global competition, according to Lux Research. China’s domestic graphene […]

Neos Therapeutics Announces $20 Million Loan Facility and Updated Total of $18 Million for its Additional Series C Financing

Dallas/Fort Worth, TX (April 23, 2014) – Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has entered into a $20 million loan facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC). The […]

Neos Therapeutics Completes $15.5 Million Additional Series C Financing

DALLAS/FORT WORTH, Texas–(BUSINESS WIRE)–Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total of $15.5 million. Investors participating in […]

Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth up to $198 Million

FREMONT, CA, Feb 24, 2014 (Marketwired via COMTEX) — Ardelyx, Inc. today announced that it has licensed to Sanofi SNY -0.19% (euronext paris:SAN) its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and regulatory milestones could potentially reach up to $198 million. […]